Inhibitory insulin-like growth factor binding protein (In-IGF-BP) has been purified to homogeneity from medium conditioned by TE89 human osteosarcoma cells by two different methods using Sephadex G-100 gel filtration, FPLC Mono Q ion-exchange, HPLC C4 reverse-phase, HPLC CN reverse-phase, and affinity chromatographies. In-IGF-BP thus purified appeared to be homogeneous and unique by the following criteria. (i) N-terminal sequence analysis yielded a unique sequence (Asp-Glu-Ala-Ile-His-Cys-Pro-Pro-GluSer-Glu-Ala-Lys-Leu-Ala). (i) Amino acid composition of In-IGF-BP revealed marked differences with the amino acid compositions of other known BPs. (iii) In-IGF-BP exhibited a single band with a molecular mass of 25 kDa under reducing conditions on sodium dodecyl sulfate/polyacrylamide gels.
'BI-labeled IGF-I or '2I-labeled IGF-II binding to In-IGF-BP.
In-IGF-BP inhibited basal, IGF-stimulated bone cell proliferation and serum-stimulated bone cell proliferation. Forskolin increased synthesis of In-IGF-BP in TE85 human osteosarcoma cells in a dose-dependent manner. Based on these findings, we conclude that In-IGF-BP is a protein that has a unique sequence and significant biological actions on bone cells.
Insulin-like growth factor binding proteins (IGF-BPs) are present in many tissues (1, 2) . Two main classes of IGF-BP exist in human serum: the growth hormone-dependent 150-kDa species and the smaller non-growth hormone-dependent 30-to 40-kDa species. The 150-kDa species consists of an acid-labile subunit and a 53-kDa acid-stable binding subunit (IGF-BP III) bound to IGF-I or IGF-II (3) . Full-length cDNA clones of human IGF-BP III have been isolated, and the complete deduced sequence of the protein has been determined (4) .
In addition to the serum BPs, IGF-BPs have been found in tissue extracts and culture media conditioned by cells (1, 2) . At least two forms, IGF-BP I and IGF-BP II, have been identified. The N-terminal sequences of IGF-BP I derived from several human sources (amniotic fluid, placental membranes, decidua, and HEP G2 hepatoma cells) are identical (5) (6) (7) (8) . The cloning and complete sequence of cDNA encoding IGF-BP I from HEP G2, human uterus, and human placental cDNA libraries have been recently reported (9) (10) (11) (12) . IGF-BP II is present in the conditioned medium (CM) from rat BRL-3A cells (13) and Madin-Darby bovine kidney (MDBK) cells (14) . The gene encoding IGF-BP II has recently been cloned from BRL-3A cDNA library (15) . Thus, a group of three BPs has been identified that bind IGF-I and IGF-II and have limited similarity in their N-terminal sequences.
The role of IGF-BPs in regulating the actions of IGFs is only now emerging. IGF-BP I and IGF-BP III have been shown to inhibit or enhance the action of the IGFs depending on the culture conditions (16) (17) (18) . These findings are consistent with a role for BPs in regulating the responsiveness of cells to IGFs.
We have recently shown that skeletal growth factor isolated from human bones is very similar, if not identical, to IGF-II (19) . The findings that human bone cell CM contains a large molecular weight form of IGF-I1 suggested that human bone cells in culture produce IGF-II and its BP (20) . We report here the isolation and characterization of a protein from human bone cell CM that binds IGF-I and IGF-II and has limited N-terminal sequence similarity with the other known BPs. IGF-BP isolated from bone cell CM was inhibitory to bone cell proliferation under all culture conditions tested. Hence, we have arbitrarily assigned a functional name to this binding protein, inhibitory IGF-BP (In-IGF-BP).
MATERIALS AND METHODS
Collection of CM. Normal human bone cells (HBC) were isolated and cultured as described (20) . HBC and human osteosarcoma cells TE89 and TE85 (obtained from American Type Culture Collection) were grown in monolayer cultures in Petri dishes or in roller bottles in Dulbecco's modified eagle's medium (DMEM) supplemented with 10%6 calf serum. Upon 60-80% confluence, the cells were rinsed once with serum-free DMEM and maintained in serum-free medium for CM collections. The CM samples (2-day collections) were pooled and clarified at 500 x g to remove cellular debris.
Purification of BP. CM was acidified with acetic acid (1 M), concentrated using a YM5 membrane (Amicon), and used for purification of BPs by two different procedures. Procedure 1. (i) Gel filtration: The CM concentrate was lyophilized, reconstituted in 2.5 ml of 1 M acetic acid, and applied to a Sephadex G-100 column (2.5 x 100 cm). The proteins were eluted with 1 M acetic acid and 2-ml fractions were collected. The fractions containing BP activity were pooled and lyophilized. (ii) FPLC: Sephadex G-100 pool was reconstituted with 20 mM Tris HCl (pH 8.0) and applied to a Mono Q ion-exchange column. The proteins were eluted with a gradient of NaCl from 0 mM to 500 mM NaCl in 60 min, and 2-min fractions were collected. (iii) HPLC C4: The FPLC Mono Q peak containing BP activity was concentrated and then subjected to HPLC reverse-phase chromatography in 0.1% trifluoroacetic acid (TFA) using a 4.6 x 250 mm C4 column (Bio-Rad RP304). The unbound proteins were eluted for 5 min with 15% acetonitrile in 0.1% TFA. Bound proteins were eluted by a linear 15-40% acetonitrile gradient in 125 min. Two-minute fractions were collected. (iv) HPLC CN: Final purification of BP was achieved by HPLC reversephase chromatography in 0.1% TFA using a 3.9 x 150 mm tkBondapak CN column (Waters) with a 1-propanol gradient (20-40% in 100 min).
Procedure 2. (i) IGF-I affinity: TE89 CM concentrate was dialyzed against phosphate-buffered saline (PBS) (pH 7.4) and applied to the affinity column (composed of recombinant human IGF-I coupled to CNBr-activated Sepharose 4B). The unbound proteins were eluted with PBS and the bound proteins were eluted with 4 M guanidine hydrochloride (pH 7.4). (ii) HPLC C4: IGF-I affinity bound fraction was dialyzed against 0.1% TFA and separated on HPLC reverse-phase chromatography as described above using a gradient of acetonitrile from 15% to 40% in 125 min.
Assays. At each step during the purification of BP, aliquots of fractions were diluted with DMEM containing 1 mg of bovine serum albumin per ml and used for the following assays. (i) BP assay: This assay was based on the principle that polyethylene glycol (PEG) precipitated the large molecular weight BP-IGF complex and not the small molecular weight IGF (18) . Briefly, 50 p.1 of sample was incubated with 25,000-50,000 cpm of 1251-labeled IGF-I or IGF-II (1251-IGF-I or 125I-IGF-II) for 60 min at room temperature in 0.1 M Hepes/0. 1% bovine serum albumin/0.1% Triton X-100/44 mM Na2CO3/0.02% NaN3, pH 6.0 (250-pul volume). Bound and free 125I-IGF-I or 125I-IGF-II were separated by adding 100 p.1 of 2% immune serum globulin and 500 ,ul of 25% PEG (Mr 8000) and centrifuging. Specific binding was determined by subtracting nonspecific binding (in the presence of excess of unlabeled IGF-I) from total binding. IGF-I and IGF-II were radiolabeled with Na125I by a modification of the chloramine-T method as described (19) . (ii) Radioreceptor assay for IGF-IL: H-35 rat hepatoma cells, which contain abundant IGF-II but not IGF-I receptors, were used as the receptor source (21) . IGF-I purified from bone matrix extract was used as standard and tracer. The assay was carried out as described (19) . (iii) Cell proliferation assay: The proliferation of bone cells in serum-free culture was assayed by the incorporation of [3H]thymidine into tricholoroacetic acid-precipitable material (22) .
Cross-Linking Studies. One nanogram of purified BP was incubated with 40,000 cpm of 125I-IGF-II in the presence (10 ng of unlabeled IGF-II) or absence of competitor. The binding was performed in 0.1 ml of 50 mM sodium phosphate buffer/0.1% bovine serum albumin, pH 6.5, for 60 min at room temperature. Two microliters of 25 mM disuccinimidyl suberate (freshly prepared in dimethyl sulfoxide) was added and the incubation was continued for an additional 20 min. At the end of the incubation, 100/l of2x electrophoresis sample buffer was added and the samples were boiled for 3 min.
BP-1251-IGF-II complex was separated from free 1251-IGF-II by electrophoresis using a 15% slab gel. The gel was air dried and exposed to Kodak X-Omat AR film with the use of an intensifying screen for 7 days at -70'C.
Amino Acid Analysis. Amino acid composition was analyzed with an Applied Biosystems model 420 instrument after hydrolysis in evacuated tubes for 24 hr at 110'C with 6 M HCI/0.5% phenol. N-terminal sequences were determined as described (19) .
RESULTS
Isolation of In-IGF-BP. Previous studies have shown that human bone cells in culture produce IGF-II in vitro (19, 20 To further purify the BP, peaks 1 and 2 (fractions 37-51) from the TE89 CM were pooled and subjected to Mono Q anion-exchange chromatography using a gradient of NaCl (data not shown). Again, there were two peaks of BP activity. Peak 1 eluted at 0.1 M NaCl (fractions 9-15), whereas peak 2 eluted at 0.2 M NaCi (fractions 17-25). As was found using gel filtration chromatography, peak 1 was a strong competitor and peak 2 was a weak competitor for the binding of 125I[ IGF-II to H-35 cells. Fractions (9-15) containing peak 1 (In-IGF-BP) were pooled and analyzed further.
Upon HPLC reverse-phase chromatography (using a C4 column), In-IGF-BP activity (as determined by the inhibition of 125I-IGF-II binding to H-35 cells) eluted between 31% and 32% acetonitrile (fractions 45-48) (data not shown). Although fractions 49-54 exhibited some BP activity (by PEG precipitation of 125I-IGF-II-BP complex), none of these fractions inhibited binding of 125I-IGF-II to H-35 cells. Further purification of In-IGF-BP (fractions 45-48) was achieved by rechromatographing the active fractions on an HPLC CN column using a 1-propanol gradient. In-IGF-BP eluted at 36% 1-propanol (fractions 54-56). The fractions that contained BP activity also exhibited I251-IGF-II-competing activity. This preparation appeared to be homogeneous as it produced a single sequence signal on N-terminal analysis.
In order to confirm that the N-terminal sequence obtained was not from a major contaminating protein in the BP preparation, In-IGF-BP was purified by an alternate procedure involving affinity chromatography. The BPs were separated from the other proteins in TE89 CM by chromatography on IGF-I linked to Sepharose 4B. The In-IGF-BP was further purified from other BPs by HPLC reverse-phase chromatography using a C4 column as described in procedure 1. Fractions 44 and 45, which contained the In-IGF-BP activity, were used for subsequent chemical and biological characterization studies. The recovery of In-IGF-BP during purification was 18% ( Table 1) .
Characterization of In-IGF-BP. Chemical. Fig. 2 Laemmli (23) . The gel was silver stained (22) Biological. Purified In-IGF-BP inhibited chicken bone cell proliferation in serum-free culture in a dose-dependent manner (Fig. 4) . In addition, purified In-IGF-BP inhibited IGF-II-induced chicken bone cell proliferation at submaximal concentrations. For example, at 3 ng/ml, IGF-II stimulated [3H]thymidine incorporation 2.2-fold over control in chicken calvarial cells. A dose-dependent inhibition of 3 ng of IGF-II-stimulated [3H]thymidine incorporation per ml was observed with increasing concentrations of 25-kDa In-IGF-BP (Fig. 4) . Although the IGF-BP III has been reported to enhance rather than inhibit the action of IGF-I when cells were pretreated with the BP, pretreatment of bone cells with In-IGF-BP did not alter the BP's inhibitory effect. In contrast to the effect of In-IGF-BP, IGF-BP I (from human placenta) at concentrations up to 30 ng did not inhibit IGF-II-induced cell proliferation. The inhibitory effect of a fixed concentration of In-IGF-BP could be overcome by increasing the concentrations of IGF-I (Fig. 5) . In addition to inhibiting IGF-induced [3H]Thymidine incorporation was significantly decreased (P < 0.001) in the presence of In-IGF-BP at all concentrations of serum tested.
wells inhibited serum-stimulated [3H]thymidine incorporation by about 50-70% (Fig. 6) .
Regulation of In-IGF-BP Production. Forskolin, a stimulator of cAMP production, increased production of In-IGF-BP in TE85 cells in a dose-dependent manner ( Table 2 ). The maximum effect of >8-fold increase in In-IGF-BP production was seen at 10 gM forskolin. 1,9-Dideoxyforskolin, an analog of forskolin that does not stimulate cAMP production had no effect on In-IGF-BP production by TE85 cells. Consistent with these results, N6,02'-dibutyryladenosine 3',5'-cyclic monophosphate stimulated In-IGF-BP production in TE85 cells (data not shown).
DISCUSSION
In this study, we have discovered a unique human IGF-BP produced by human TE89 osteosarcoma cells and probably by normal HBC as well. This IGF-BP is a strong inhibitor of IGF-induced cell proliferation and is different from the other known IGF-BPs in size, N-terminal sequence, and amino acid composition. Comparison of the N-terminal amino acid sequence of In-IGF-BP to those purified from human amniotic fluid, serum, BRL-3A CM, and MDBK CM (4, 5, 9, 13, 14) reveals that these sequences are different for each BP but have some similarities. Interestingly, amino acid residues at positions 6 (Cys), 8 (Pro), 14 family (Fig. 2) . In-IGF-BP has the most identity with IGF-BP I but even when aligned to give maximum sequence identity, 9 of 15 residues are different. In addition, comparison of the amino acid composition of the two proteins reveals marked differences. Similarly, comparison of the In-IGF-BP with those of IGF-BP II and IGF-BP III demonstrates marked differences in N-terminal amino acid sequences and in amino acid composition. Moreover, based on the sequence data, it is unlikely that In-IGF-BP is a truncated form of an IGF receptor. Together, these observations suggest that In-IGF-BP originates from a gene that is yet to be isolated.
The idea of IGF BPs being inhibitory has been advanced by other workers (1, 2 (iii) Serum is the strongest stimulator of bone cell proliferation yet discovered and the addition of In-IGF-BP (10 ng/ml) inhibited 50% of this effect. This again emphasizes the importance of the IGFs in the regulation of bone cell proliferation and the importance of In-IGF-BP in IGF action. (iv) The amount of In-IGF-BP found in the CM of HBC was relatively high (10-50 ng/ml). Moreover this concentration produced maximum inhibition in our chicken bone cell proliferation assay system. Thus adequate amounts are present in the CM for In-IGF-BP to have a strong physiological action. (v) Our In-IGF-BP was very potent in inhibiting chicken bone cell proliferation, severalfold more than another IGF BP reported to be an inhibitor of cell proliferation, IGF-BP I. In addition to inhibiting cell proliferation, IGF-BP I has been shown to increase IGF-I-induced cell proliferation in muscle cells (18) . Similarly, De Mellow and Baxter (17) have shown that IGF-BP III can either inhibit or potentiate IGF-stimulated [3H]thymidine incorporation in neonatal skin fibroblasts, depending on the incubation conditions used. In contrast to other IGF BPs, our In-IGF-BP did not stimulate cell proliferation under any in vitro condition. (vi) If In-IGF-BP has a regulatory function, it should be possible to alter its secretion rate. In this regard we found that forskolin stimulated the production of In-IGF-BP in a dosedependent manner. Based on these observations it follows that In-IGF-BP could be an important physiological regulator of IGF action in bone cells.
A major unresolved issue with respect to the function of In-IGF-BP is whether other cells produce the same or a similar inhibitory BP. Various other cell types have been shown to produce BPs [liver (13, 18) , kidney (14) , muscle (25) , skin fibroblasts (26, 27) , granulosa (28) , breast cancer (29), neuroblastoma (30)], including low molecular mass 24-kDa forms (26, 29, 30) . In addition, low molecular mass inhibitory BPs have been reported in serum (2) . Whether these BPs are potent inhibitors of IGF action or are related to the bone In-IGF-BP has not been determined. If, like bone, other tissues produce potent inhibitory IGF BPs, such proteins could function throughout the body to provide tissue IGFs on different tissues and the fact that the IGFs function as hormones as well as local factors.
